Tumor-suppressive activity of retinoic acid receptor-β in cancer

Cancer Letters

Volumn 253, Issue 1, 2007, Pages 14-24

  Xu, Xiao Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; Methylation; RAR 2; RAR 4; Retinoids; Tumorigenesis

Indexed keywords

RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; RETINOIC ACID RECEPTOR BETA4; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; DRUG ACTIVITY; DRUG EFFECT; DRUG RECEPTOR BINDING; ESOPHAGUS CANCER; HUMAN; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SHORT SURVEY; UTERINE CERVIX CANCER;

MUS MUSCULUS;

EID: 33847714231     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.019     Document Type: Review

References (110)

1. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem. Biophys. Acta 605 (1980) 33-91
2. Sporn M.B., Roberts A.B., and Goodman D.S. The Retinoids: Biology, Chemistry, and Medicine. second ed. (1994), Raven Press, New York
3. Xu X.-C., and Lotan R. Aberrant expression and function of retinoid receptors in cancer. In: Nau H., and Blaner W.S. (Eds). Handbook of Experimental Pharmacology (1999), Springer, Berlin, New York 323-343
4. Soprano D.R., Qin P., and Soprano K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24 (2004) 201-221
5. Hong W.K., Endicott J., Itri L.M., Doos W., Batsakis J.G., Bell R., et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315 (1986) 1501-1505
6. Lippman S.M., Batsakis J.G., Toth B.B., Weber R.S., Lee J.J., Martin J.W., et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N. Engl. J. Med. 328 (1993) 15-20
7. Meyskens Jr. F.L., Surwit E., Moon T.E., Childers J.M., Davis J.R., Dorr R.T., et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J. Natl. Cancer Inst. 86 (1994) 539-543
8. Misset J.L., Mathe G., Santelli G., Gouveia J., Homasson J.P., Sudre M.C., et al. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect. Prev. 9 (1986) 167-170
9. Moon T.E., Levine N., Cartmel B., Bangert J.L., Rodney S., Dong Q., et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 949-956
10. Hong W.K., Lippman S.M., Itri L.M., Karp D.D., Lee J.S., Byers R.M., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323 (1990) 795-801
11. Pastorino U., Infante M., Maioli M., Chiesa G., Buyse M., Firket P., et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol. 11 (1993) 1216-1222
12. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334 (1996) 1145-1149
13. van Zandwijk N., Dalesio O., Pastorino U., de Vries N., and van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 92 (2000) 977-986
14. Lippman S.M., Lee J.J., Karp D.D., Vokes E.E., Benner S.E., Goodman G.E., et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 93 (2001) 605-618
15. Khuri F.R., Lee J.J., Lippman S.M., Kim E.S., Cooper J.S., Benner S.E., et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst. 98 (2006) 441-450
16. Toulouse A., Loubeau M., Morin J., Pappas J.J., Wu J., and Bradley W.E. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis. FASEB J. 14 (2000) 1224-1232
17. Zhuang Y., Faria T.N., Chambon P., and Gudas L.J. Identification and characterization of retinoic acid receptor beta(2) target genes in F9 teratocarcinoma cells. Mol. Cancer Res. 1 (2003) 619-630
18. Li M., Song S., Lippman S.M., Zhang X.K., Liu X., Lotan R., and Xu X.C. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 21 (2002) 411-418
19. 2 expression. Oncogene 24 (2005) 8268-8276
20. Wallden B., Emond M., Swift M.E., Disis M.L., and Swisshelm K. Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells. BMC Cancer 5 (2005) 140-153
21. 2 on tumor cell growth and gene expression through binding to and inhibiting RhoA. Cancer Res. 66 (2006) 7111-7118
22. Grubbs C.J., Lubet R.A., Atigadda V.R., Christov K., Deshpande A.M., Tirmal V., et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 27 (2006) 1232-1239
23. Lippman S.M., Lee J.J., Martin J.W., El-Naggar A.K., Xu X., Shin D.M., et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin. Cancer Res. 12 (2006) 3109-3114
24. Wu K., Dupre E., Kim H., Tin U.C., Bissonnette R.P., Lamph W.W., et al. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res. Treat. 96 (2006) 147-157
25. Xu H., Cheepala S., McCauley E., Coombes K., Xiao L., Fischer S.M., et al. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression. Clin. Cancer Res. 12 (2006) 969-979
26. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10 (1996) 940-954
27. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
28. de The H., Lavau C., Marchio A., Chomienne C., Degos L., and Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66 (1991) 675-684
29. Zhu J., Zhou J., Peres L., Riaucoux F., Honore N., Kogan S., et al. Sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7 (2005) 143-153
30. Zhou J., Peres L., Honore N., Nasr R., Zhu J., and de The H. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc. Natl. Acad. Sci. USA 103 (2006) 9238-9243
31. Rego E.M., Ruggero D., Tribioli C., Cattoretti G., Kogan S., Redner R.L., and Pandolfi P.P. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene 25 (2006) 1974-1979
32. Garcia M., de The H., Tiollais P., Samarut J., and Dejean A. A hepatitis B virus pre-S-retinoic acid receptor beta chimera transforms erythrocytic progenitor cells in vitro. Proc. Natl. Acad. Sci. USA 90 (1993) 89-93
33. Finzi E., Blake M.J., Celano P., Skouge J., and Diwan R. Cellular localization of retinoic acid receptor-gamma expression in normal and neoplastic skin. Am. J. Pathol. 140 (1992) 1463-1471
34. Hu L., Crowe D.L., Rheinwald J.G., Chambon P., and Gudas L.J. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res. 51 (1991) 3972-3981
35. Houle B., Leduc F., and Bradley W.E. Implication of RAR-β in epidermoid (squamous) lung cancer. Genes Chromosomes Cancer 3 (1991) 358-366
36. Swisshelm K., Ryan K., Lee X., Tsou H.C., Peacocke M., and Sager R. Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 5 (1994) 133-141
37. Xu X.C., Clifford J.L., Hong W.K., and Lotan R. Detection of nuclear retinoic acid receptor mRNA in histological tissue sections using nonradioactive in situ hybridization histochemistry. Diagn. Mol. Pathol. 3 (1994) 122-131
38. Xu X.C., Ro J.Y., Lee J.S., Shin D.M., Hong W.K., and Lotan R. Differential expression of nuclear retinoic acid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 54 (1994) 3580-3587
39. Lotan R., Xu X.C., Lippman S.M., Ro J.Y., Lee J.S., Lee J.J., et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med. 332 (1995) 1405-1410
40. Widschwendter M., Berger J., Daxenbichler G., Muller-Holzner E., Widschwendter A., Mayr A., et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 57 (1997) 4158-4161
41. Xu X.C., Sneige N., Liu X., Nandagiri R., Lee J.J., Lukmanji F., et al. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res. 57 (1997) 4992-4996
42. Xu X.C., Sozzi G., Lee J.S., Lee J.J., Pastorino U., Pilotti S., et al. Suppression of nuclear retinoic acid receptor β in non-small cell lung cancer in vivo: implications in lung cancer development. J. Natl. Cancer Inst. 89 (1997) 624-629
43. Xu X.C., Lee J.S., Lee J.J., Morice R.C., Liu X., Lippman S.M., et al. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J. Natl. Cancer Inst. 91 (1999) 1317-1321
44. Xu X.C., Liu X., Tahara E., Lippman S.M., and Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res. 59 (1999) 2477-2483
45. Qiu H., Zhang W., El-Naggar A.K., Lippman S.M., Lin P., Lotan R., et al. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis. Am. J. Pathol. 155 (1999) 1519-1523
46. Xu X.C., Stier U., Rosewicz S., El-Naggar A.-K., and Lotan R. Selective suppression of nuclear retinoic acid receptor beta gene expression in human pancreatic cancers. Int. J. Oncol. 8 (1996) 445-451
47. Xu X.C., Mitchell M.F., Silva E., Jetten A., and Lotan R. Decreased expression of retinoic acid receptors, transforming growth factor beta, involucrin, and cornifin in cervical intraepithelial neoplasia. Clin. Cancer Res. 5 (1999) 1503-1508
48. Lotan Y., Xu X.C., Shalev M., Lotan R., Williams R., Wheeler T.M., et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J. Clin. Oncol. 18 (2000) 116-121
49. P.J. Bastian, J. Ellinger, L.C. Heukamp, P. Kahl, S.C. Muller, A. von Rucker, Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy, Eur Urol, in press.
50. Lewis C.M., Cler L.R., Bu D.W., Zochbauer-Muller S., Milchgrub S., Naftalis E.Z., et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin. Cancer Res. 11 (2005) 166-172
51. Bean G.R., Scott V., Yee L., Ratliff-Daniel B., Troch M.M., Seo P., et al. Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 790-798
52. Kim Y.T., Lee S.H., Sung S.W., and Kim J.H. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?. Ann. Thorac. Surg. 79 (2005) 1180-1188
53. Grote H.J., Schmiemann V., Geddert H., Rohr U.P., Kappes R., Gabbert H., et al. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer. Int. J. Cancer 116 (2005) 720-725
54. Fujiwara K., Fujimoto N., Tabata M., Nishii K., Matsuo K., Hotta K., et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11 (2005) 1219-1225
55. Wang Y., Fang M.Z., Liao J., Yang G.Y., Nie Y., Song Y., et al. Hypermethylation-associated inactivation of retinoic acid receptor beta in human esophageal squamous cell carcinoma. Clin. Cancer Res. 9 (2003) 5257-5263
56. Jeronimo C., Henrique R., Hoque M.O., Ribeiro F.R., Oliveira J., Fonseca D., et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 10 (2004) 4010-4014
57. Ayoub J., Jean-Francois R., Cormier Y., Meyer D., Ying Y., and Major P. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: implications for chemoprevention of lung cancer. J. Clin. Oncol. 17 (1999) 3546-3552
58. Kurie J.M., Lotan R., Lee J.J., Lee J.S., Morice R.C., Liu D.D., et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl. Cancer Inst. 95 (2003) 206-214
59. Grunt T.W., Puckmair K., Tomek K., Kainz B., and Gaiger A. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells. Biochem. Biophys. Res. Commun. 329 (2005) 1253-1259
60. Lian F., Hu K.Q., Russell R.M., and Wang X.D. Beta-Cryptoxanthin suppresses the growth of immortalized human bronchial epithelial cells and non-small-cell lung cancer cells and up-regulates retinoic acid receptor beta expression. Int. J. Cancer 119 (2006) 2084-2089
61. Berg W.J., Nanus D.M., Leung A., Brown K.T., Hutchinson B., Mazumdar M., et al. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin. Cancer Res. 5 (1999) 1671-1675
62. Geradts J., Chen J.-Y., Russell E.K., Yankaskas J.R., Nieves L., and Minna J.D. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ. 4 (1993) 799-809
63. Lin B., Chen G.Q., Xiao D., Kolluri S.K., Cao X., Su H., et al. Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol. Cell Biol. 20 (2000) 957-970
64. 2 through the PI3K/Akt signaling pathway. Mol. Endocrinol. 20 (2006) 2109-2121
65. Wang X.F., Qian D.Z., Ren M., Kato Y., Wei Y., Zhang L., et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin. Cancer Res. 11 (2005) 3535-3542
66. Sirchia S.M., Ren M., Pili R., Sironi E., Somenzi G., Ghidoni R., et al. Endogenous reactivation of the RARβ2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62 (2002) 2455-2461
67. Ferrari N., Pfahl M., and Levi G. Retinoic acid receptor gamma1 (RARgamma1) levels control RARbeta2 expression in SK-N-BE2(c) neuroblastoma cells and regulate a differentiation-apoptosis switch. Mol. Cell Biol. 18 (1998) 6482-6492
68. Suh Y.A., Lee H.Y., Virmani A., Wong J., Mann K.K., Miller Jr. W.H., et al. Loss of retinoic acid receptor β gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res. 62 (2002) 3945-3949
69. Verma A.K., Shoemaker A., Simsiman R., Denning M., and Zachman R.D. Expression of retinoic acid nuclear receptors and tissue transglutaminase is altered in various tissues of rats fed a vitamin A-deficient diet. J. Nutr. 122 (1992) 2144-2152
70. Kato S., Mano H., Kumazawa T., Yoshizawa Y., Kojima R., and Masushige S. Effect of retinoid status on alpha, beta and gamma retinoic acid receptor mRNA levels in various rat tissues. Biochem. J. 286 (1992) 755-760
71. Guo X., Ruiz A., Rando R.R., Bok D., and Gudas L.J. Esterification of all-trans-retinol in normal human epithelial cell strains and carcinoma lines from oral cavity, skin and breast: reduced expression of lecithin:retinol acyltransferase in carcinoma lines. Carcinogenesis 21 (2000) 1925-1933
72. Xu X.C., Zile M.H., Lippman S.M., Lee J.S., Lee J.J., Hong W.K., et al. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions which occurs less frequently than binding to normal tissue increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res. 55 (1995) 5507-5551
73. Ren M., Pozzi S., Bistulfi G., Somenzi G., Rossetti S., and Sacchi N. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol. Cell Biol. 25 (2005) 10591-10603
74. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., and Faretta M. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295 (2002) 1079-1082
75. Liu Z., Zhang L., Ding F., Li J., Guo M., Li W., et al. 5-Aza-2′-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett. 230 (2005) 271-283
76. Virmani A.K., Rathi A., Zochbauer-Muller S., Sacchi N., Fukuyama Y., and Bryant D. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92 (2000) 1303-1307
77. Cote S., and Momparler R.L. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs 8 (1997) 56-61
78. Wang X.D., Liu C., Bronson R.T., Smith D.E., Krinsky N.I., and Russell M. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J. Natl. Cancer Inst. 91 (1999) 60-66
79. Vuillemenot B.R., Pulling L.C., Palmisano W.A., Hutt J.A., and Belinsky S.A. Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carcinogenesis 25 (2004) 623-629
80. Song S., and Xu X.C. Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem. Biophys. Res. Commun. 281 (2001) 872-877
81. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63 (2003) 7563-7570
82. Kim J.S., Lee H., Kim H., Shim Y.M., Han J., Park J., et al. Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 3443-3450
83. Berard J., Gaboury L., Landers M., De Repentigny Y., Houle B., Kothary R., et al. Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene. EMBO J. 13 (1994) 5570-5580
84. Xu X.C., Lee J.J., Wu T.T., Hoque A., Ajani J.A., and Lippman S.M. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 826-829
85. Sommer K.M., Chen L.I., Treuting P.M., Smith L.T., and Swisshelm K. Elevated retinoic acid receptor beta(4) protein in human breast tumor cells with nuclear and cytoplasmic localization. Proc. Natl. Acad. Sci. USA 96 (1999) 8651-8656
86. Hayashi K., Goodison S., Urquidi V., Tarin D., Lotan R., and Tahara E. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4. Int. J. Oncol. 22 (2003) 623-629
87. Khuri F.R., Lotan R., Kemp B.L., Lippman S.M., Wu H., and Feng L. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J. Clin. Oncol. 18 (2000) 2798-2804
88. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., and Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7 (2001) 861-867
89. Soria J.C., Xu X.C., Liu D.D., Lee J.J., Kurie J., and Morice R.C. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J. Natl. Cancer Inst. 95 (2003) 165-168
90. Nagpal S., Zelent A., and Chambon P. RAR-beta4, a retinoic acid receptor isoform is generated from RAR-beta 2 by alternative splicing and usage of a CUG initiator codon. Proc. Natl. Acad. Sci. USA 89 (1992) 2718-2722
91. Zelent A., Mendelsohn C., Kastner P., Krust A., Garnier J.M., and Ruffenach F. Differentially expressed isoforms of the mouse retinoic acid receptor beta generated by usage of two promoters and alternative splicing. EMBO J. 10 (1991) 71-81
92. Peng X., Maruo T., Cao Y., Punj V., Mehta R., and Das Gupta T.K. A novel RARbeta isoform directed by a distinct promoter P3 and mediated by retinoic acid in breast cancer cells. Cancer Res. 64 (2004) 8911-8918
93. Petty W.J., Li N., Biddle A., Bounds R., Nitkin C., and Ma Y. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J. Natl. Cancer Inst. 97 (2005) 1645-1651
94. Houle B., Pelletier M., Wu J., Goodyer C., and Bradley W.E. Fetal isoform of human retinoic acid receptor beta expressed in small cell lung cancer lines. Cancer Res. 54 (1994) 365-369
95. Berard J., Delabre J.F., Garneau H., Bellehumeur C., and Carrier M.E. Lung tumorigenesis in transgenic mice expressing RAR-beta1 and RAR-beta3 antisense mRNA. Lung Cancer 41 S2 (2003) S122
96. Chen L.I., Sommer K.M., and Swisshelm K. Downstream codons in the retinoic acid receptor beta-2 and beta-4 mRNAs initiate translation of a protein isoform that disrupts retinoid-activated transcription. J. Biol. Chem. 277 (2002) 35411-35421
97. Soprano D.R., Scanlon E., Shukri M., Zhang Z.P., and Soprano K.J. Murine RARbeta4 displays reduced transactivation activity, lower affinity for retinoic acid, and no anti-AP1 activity. J. Cell Biochem. 77 (2000) 604-614
98. Croce C.M., and Calin G.A. miRNAs, cancer and stem cell division. Cell 122 (2005) 6-7
99. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., and Burge C.B. Prediction of mammalian microRNA targets. Cell 115 (2003) 787-798
100. Houle B., Rochette-Egly C., and Bradley W.E. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA 90 (1993) 985-989
101. Berard J., Laboune F., Mukuna M., Masse S., Kothary R., and Bradley W.E. Lung tumors in mice expressing an antisense RARbeta2 transgene. FASEB J. 10 (1996) 1091-1097
102. Faria T.N., Mendelsohn C., Chambon P., and Gudas L.J. The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest. J. Biol. Chem. 274 (1999) 26783-26788
103. Treutin P.M., Chen L.I., Buetow B.S., Zeng W., Birkebak T.A., Seewaldt V.L., et al. Retinoic acid receptor beta2 inhibition of metastasis in mouse mammary gland xenografts. Breast Cancer Res. Treat. 72 (2002) 79-88
104. Cheung B., Hocker J.E., Smith S.A., Norris M.D., Haber M., and Marshall G.M. Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene 17 (1998) 751-759
105. McGregor F., Wagner E., Felix D., Soutar D., Parkinson K., and Harrison P.R. Inappropriate retinoic acid receptor-beta expression in oral dysplasias: correlation with acquisition of the immortal phenotype. Cancer Res. 57 (1997) 3886-3889
106. McGregor F., Muntoni A., Fleming J., Brown J., Felix D.H., MacDonald D.G., et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res. 62 (2002) 4757-4766
107. Muntoni A., Fleming J., Gordon K.E., Hunter K., McGregor F., Parkinson E., et al. Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-beta: but p53 mutations are not necessarily required. Oncogene 22 (2003) 7804-7808
108. Lin F., Xiao D., Kolluri S.K., and Zhang X. Unique anti-activator protein-1 activity of retinoic acid receptor beta. Cancer Res. 60 (2000) 3271-3280
109. Delage B., Bairras C., Buaud B., Pallet V., and Cassand P. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. Int. J. Cancer 116 (2005) 839-846
110. J. Huang, T.T. Wu, Z.D. Liang, Y. Jiang, H. Zhang, X.C. Xu, Tumor-suppressive effect of retinoid receptor-induced gene-1 (RRIG1) in esophageal cancer, Cancer Res., accepted for publication.